Search

Andrew Canonico, MD
Marius Fassbinder, MD
Luna Chaaban, MD
Luna Chaaban, MD, joined the department of Anesthesiology at The GW Medical Faculty Associates in Jan. 2025. She will be working at the GW Hospital in general anesthesia and critical care medicine settings.
Lisa E. Menke, AuD
Dr. Lisa E. Raho is a Doctor of Audiology at The GW Medical Faculty Associates within the division of Otolaryngology. She graduated from Providence College in 2013 with a Bachelor of Arts (B.A.) degree in Elementary and Special Education. Dr. Raho earned her Doctor of Audiology degree (Au.D.) from…
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test…
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testosterone can cause the growth of prostate cancer cells, and Apalutamide blocks the use of testosterone by the tumor…
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
Primary Outcome Measures: Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0. [Time Frame: Approximately 2 years] The type, incidence, relatedness and severity of treatment emergent adverse events of EG-70 as assessed by NCI-CTCAE V5.0 will be…
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer)
Primary objective to compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.
Karen Fagan, MD
Karen A. Fagan, MD, serves as the Chair of the GW Department of Medicine. In this role, Fagan provides leadership to the department’s 12 divisions, 579 faculty members including 119 full-time faculty, internal medicine residency program, and 12 accredited fellowships.
Meric Mericliler, MD
Meric Mericliler, MD, has joined the George Washington (GW) University Cancer Center and The GW Medical Faculty Associates as a hematologist-oncologist specializing in benign hematology.